HOME
Leading the way to a cure

LUPUS NEWS

Experimental Lupus Therapy from Argos in Partnering Talks after Strong Phase 1

June 8, 2012

The experimental lupus treatment being developed by Argos Therapeutics is showing promise in early stage clinical trials, but the questions remain whether it’s enough progress to attract interest from a potential pharmaceutical partner.

Argos released positive phase 1 clinical trial results for AGS-009 at the 2012 European League Against Rheumatism Congress (EULAR) in Berlin, Germany this week. Argos has been clear about its desire to work with a partner to develop AGS-009. The Durham, North Carolina immunotherapy company needs the financial support of a larger partner for the lupus candidate because most of its resources are directed to its lead therapeutic candidate, an experimental kidney cancer treatment. Argos raised $25 million in a series D round in April with proceeds intended for studying AGS-003 in phase 3 clinical trials.

AGS-009 was discovered through dendritic cell research from Argos. The company developed the compound following a $1 million grant by the Alliance for Lupus Research in 2005 to develop a monoclonal antibody-based lupus therapy. AGS-009 is a monoclonal antibody that has the ability to bind and neutralize interferon alpha, a protein that induces inflammation. Interferon alpha is activated and produced by dendritic cells. Patients who received AGS-009 in the phase 1 study shifted toward normal interferon alpha levels after a single dose. Patients who received a placebo showed no such change.

****

Click here to read more

Source: MedCity News

 

 


Experimental Lupus Therapy from Argos in Partnering Talks after Strong Phase 1

June 8, 2012

The experimental lupus treatment being developed by Argos Therapeutics is showing promise in early stage clinical trials, but the questions remain whether it’s enough progress to attract interest from a potential pharmaceutical partner.

Argos released positive phase 1 clinical trial results for AGS-009 at the 2012 European League Against Rheumatism Congress (EULAR) in Berlin, Germany this week. Argos has been clear about its desire to work with a partner to develop AGS-009. The Durham, North Carolina immunotherapy company needs the financial support of a larger partner for the lupus candidate because most of its resources are directed to its lead therapeutic candidate, an experimental kidney cancer treatment. Argos raised $25 million in a series D round in April with proceeds intended for studying AGS-003 in phase 3 clinical trials.

AGS-009 was discovered through dendritic cell research from Argos. The company developed the compound following a $1 million grant by the Alliance for Lupus Research in 2005 to develop a monoclonal antibody-based lupus therapy. AGS-009 is a monoclonal antibody that has the ability to bind and neutralize interferon alpha, a protein that induces inflammation. Interferon alpha is activated and produced by dendritic cells. Patients who received AGS-009 in the phase 1 study shifted toward normal interferon alpha levels after a single dose. Patients who received a placebo showed no such change.

****

Click here to read more

Source: MedCity News